BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Paradigms Foundation - ECPv6.18.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://paradigms.foundation
X-WR-CALDESC:Events for Paradigms Foundation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Paris
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20260329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20261025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20270328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20271031T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260527T173000
DTEND;TZID=Europe/Paris:20260527T183000
DTSTAMP:20261013T152832Z
CREATED:20260513T082653Z
LAST-MODIFIED:20261013T152832Z
UID:14311-1779903000-1779906600@paradigms.foundation
SUMMARY:Live Webinar on the Early intervention in Multiple Sclerosis: the role of high-efficacy therapies in long-terms outcomes
DESCRIPTION:Join ParadigMS Foundation for a live webinar exploring the evolving role of early intervention and high-efficacy therapies in Multiple Sclerosis (MS). This webinar will review current evidence on long-term clinical outcomes\, treatment strategies\, and practical considerations for neurologists involved in MS care. \n\n\n\nKey Highlights\n\n\n\n\nReview of current evidence on high-efficacy therapies and long-term outcomes \n\n\n\nPractical insights into treatment selection and therapeutic sequencing \n\n\n\nClinical perspectives from internationally recognized MS experts \n\n\n\nInteractive session designed for neurologists and MS healthcare professionals \n\n\n\nLive webinar with automated translation available for international participants \n\n\n\nOpportunity to explore evolving approaches to long-term MS management\n\n\n\n\nRegister to access the webinar\n\n\n\nThis session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions. \n\n\n\n\nRegister to access the webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages\, offered by Zoom platform. \n\n\n\nThis webinar might interest you if you are:\n\n\n\n\nNeurologists with a particular interest in multiple sclerosis therapies and treatments\n\n\n\nNeurologists in training\n\n\n\nNurses engaged in the care of patients with multiple sclerosis\n\n\n\nPatient representatives\n\n\n\n\nQuestions and discussion\n\n\n\nIf there are specific questions you would like to see addressed during the session\, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations. \n\n\n\nYou will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session. \n\n\n\nTechnology used\n\n\n\nThe session will be conducted via Zoom\, with access credentials shared upon completion of your registration. \n\n\n\nTime and date\n\n\n\nThe session will be held in English on Wednesday\, 27 May 2026 from 5:30 to 6:30 p.m. CEST. \n\n\n\nInvited Speakers\n\n\n\n\n\n\n\nTjalf Ziemssen\n\n\n\nProfessor of Clinical Neuroscience at University Clinic Carl-Gustav Carus in Dresden  \n\n\n\n\n\n\n\nBart Van Wijmeersch\n\n\n\nAssociate Professor of Neurology at the University of Hasselt  \n\n\n\nFunding\n\n\n\nThis webinar is organized with the financial support of Sandoz. \n\n\n\nSandoz has not been involved in the elaboration of the presentations.
URL:https://paradigms.foundation/event/live-webinar-on-the-early-intervention-in-multiple-sclerosis-the-role-of-high-efficacy-therapies-in-long-terms-outcomes/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/05/LAU-PR3-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260613T000000
DTEND;TZID=Europe/Paris:20260613T235959
DTSTAMP:20260616T140459Z
CREATED:20251216T103224Z
LAST-MODIFIED:20260616T140459Z
UID:12647-1781308800-1781395199@paradigms.foundation
SUMMARY:Annual MS Meeting 2026
DESCRIPTION:Saturday\, June 13th – morning session\n\n\n\n\n\n\n\nOptic Neuritis Unveiled: Clinical and Imaging Perspectives\n\n\n\nIrish College\, Leuven\n\n\n\nThe Belgian Study Group for Multiple Sclerosis (BSGMS) and ParadigMS Foundation are pleased to announce the Annual MS Meeting 2026\, a scientific meeting for the Belgian MS community and allied healthcare professionals. \n\n\n\nThis year’s meeting\, entitled “Optic Neuritis Unveiled: Clinical and Imaging Perspectives\,” will focus on optic neuritis as a key clinical entity in multiple sclerosis and related disorders. The programme will combine clinical expertise with advanced imaging approaches\, highlighting how evolving diagnostic tools can support earlier diagnosis\, improved prognostication\, and optimized patient management. \n\n\n\nPictures from the meeting (by DAVID PLAS PHOTOGRAPHY) \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nScientific Programme \n\n\n\nThe meeting will feature three keynote lectures delivered by internationally recognized experts\, followed by interactive case discussions and clinical conclusions. This is an in-person meeting and no livestream will be available.  \n\n\n\n\n\n\n\n \n\n\n\nAbout the co-chairs and the keynotes speakers\n        \n            \n              \n                        \n                            About the speakers\n                        \n                    \n                        \n                            About the co-Chairs\n                        \n                    \n            \n            \n                \n\n\n\n\n\n\n\nAxel Petzold (UK) is a consultant neurologist at the National Hospital for Neurology and Neurosurgery\, Queen Square\, and at Moorfields Eye Hospital in London. His clinical and research work focuses on multiple sclerosis and optic neuritis. He is a Fellow of the Royal College of Physicians\, the Royal College of Ophthalmologists\, and the Royal College of Pathologists. Over the years\, he has been involved in a number of collaborative initiatives\, including serving as Chair for Neuro-Ophthalmology within the European Reference Networks for Rare Diseases. He has also helped develop integrated care pathways between his NHS Hospital Trusts. Prof Petzold has published widely in peer-reviewed journals and has supervised and mentored fellows and students from different countries. He remains committed to careful clinical practice\, collaborative research\, and supporting the next generation of clinicians and scientists. \n\n\n\n\n\n\n\n\n\nAnne-Catherine Chapelle (Belgium) is a neuro-ophthalmologist and pediatric ophthalmologist at the University Hospital of Liège\, where she is involved in both clinical practice and academic activities. She completed a neuro-ophthalmology fellowship in London under the supervision of Professor Gordon Plant\, gaining advanced expertise in the diagnosis and management of complex neuro-ophthalmic disorders\, including inflammatory and demyelinating diseases of the visual pathway. She subsequently completed a doctoral thesis focused on retinal ganglion cell evaluation in ischemic optic neuropathies\, with particular attention to structural and functional correlations. Her clinical and research interests center on optic nerve disorders and the use of retinal imaging\, notably optical coherence tomography (OCT)\, as a biomarker in neurological diseases. \n\n\n\n\n\n\n\n\n\n\n\n\n\nJette Lautrup Frederiksen (Denmark) is Professor of Neurology\, Senior Consultant\, MD and Doctor of Medical Sciences (DMSc) at University of Copenhagen based on thesis “A prospective Study of Acute Optic Neuritis: Clinical\, MRI. CSF\, Neurophysiological and HLA Findings”. She has 40 years of research experience in the clinical\, imaging\, neurophysiological and biomedical aspects of optic neuritis\, multiple sclerosis and neuro-ophthalmology. She is the founder of the Multiple Sclerosis Clinic at Copenhagen University Hospital Rigshospitalet Glostrup\, Denmark and head of the Optic Neuritis Clinic there. Since 2011 she has been Professor in Optic Neuritis in relation to Multiple Sclerosis at the University of Copenhagen. She is by Scholar GPS ranked No. 2 within the category Optic Neuritis lifelong and has authored more than 300 publications in international scientific journals. \n\n\n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\nBelgian Study Group for Multiple Sclerosis \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nParadigMS Foundation \n\n\n\n\n\n\nProf. Bénédicte Dubois (Belgium) is an internationally recognised neurologist and multiple sclerosis expert. She is Head of the Department of Neurology at University Hospitals Leuven\, Head of the Laboratory for Neuroimmunology\, and part-time Full Professor at the Faculty of Medicine of KU Leuven\, where she also leads the Research Group Experimental Neurology and oversees the medical clerkship centres. Alongside her leadership roles\, she is a pioneer of interdisciplinary MS care and precision medicine in Belgium\, and her translational research focuses on the neuroimmunological and genetic mechanisms underlying MS\, supported by a unique longitudinal patient database. She is also actively involved in multiple internal and external committees dedicated to education and scientific research. \n\n\n\nProf. Bart Van Wijmeersch (Belgium) is a neurologist specialised in multiple sclerosis and Associate Professor of Neurology at the University of Hasselt\, affiliated with the Biomedical Institute (BIOMED). He is Medical Director of the Rehabilitation and MS Center in Pelt\, where he leads a multidisciplinary MS team delivering comprehensive patient care. His academic and clinical work bridges immunological\, biomarker\, MRI\, electrophysiological\, and rehabilitation research in MS\, combining pre-clinical models\, clinical studies\, and translational approaches. In addition to his research and clinical leadership\, he plays an active educational role within the faculties of medicine and physiotherapy. He is a member of the Belgian Study Group of Multiple Sclerosis\, founding President of ParadigMS\, and serves on advisory boards for pharmaceutical companies active in MS research. In recognition of his scientific contributions\, he received an honorary award from the Flemish Government in 2019. \n\n\n\n \n\n\n\n            \n        \n        \n    \n\n\n\nAbstracts of the keynotes\nAxel Petzold (UK) – Clinical Aspects of Optic Neuritis \n\n\n\nOptic neuritis (ON) is an inflammatory disorder of the optic nerve and a common cause of visual loss\, particularly in young and middle-aged adults. Clinically\, ON presents with subacute unilateral visual loss\, periocular pain exacerbated by eye movement\, impaired colour vision\, and visual field defects. Although many patients recover high-contrast visual acuity\, residual deficits in contrast sensitivity\, colour perception\, visual fields\, and visual fatigue are common. Clinically a common cause in a Caucasian population is multiple sclerosis (MS). Some clinical features such as bilateral involvement\, severe visual loss\, poor recovery\, or absence of pain should prompt urgent evaluation for other ON subgroups. \n\n\n\nThe clinical spectrum of ON is heterogeneous. MS-associated ON (MS-ON) remains frequent in neurological practise. IN MS-ON visual recovery is typically good. In contrast\, aquaporin-4 antibody-associated ON (AQP4-ON) is typically more severe\, may be bilateral\, and carries a high risk of permanent visual disability and future relapses. Myelin oligodendrocyte glycoprotein antibody-associated ON (MOG-ON) often presents with marked optic disc swelling and exquisite corticosteroid responsiveness. The relapse risk in MOG-ON varies\, with about half of all cases being monophasic. Accurate early phenotyping of ON is therefore central to prognosis and long-term management. \n\n\n\nDiagnosis is clinical\, supported by magnetic resonance imaging (MRI)\, serum antibody testing (AQP4-IgG and MOG-IgG)\, and optical coherence tomography (OCT). Acute management commonly includes high-dose corticosteroids to accelerate recovery\, with escalation therapies such as plasma exchange or IVIG considered in severe or refractory cases. Secondary prevention strategies depend on aetiology and relapse risk\, particularly in antibody-mediated disease and in patients at high risk of developing MS. \n\n\n\nBeyond acute treatment\, clinical care must address visual rehabilitation\, mental health burden\, and relapse surveillance. Persistent pain\, visual fatigue\, and anxiety about recurrence are frequent but under-recognised sequelae. Despite advances in immunotherapy and diagnostics\, substantial global variability remains in access to timely imaging\, antibody testing\, specialist care\, and relapse-preventive therapy. \n\n\n\nON is therefore both a neurological emergency and a window into systemic inflammatory disease. Optimising clinical outcomes requires early recognition\, aetiology-driven management\, structured follow-up\, and equitable access to specialist services. \n\n\n\nAnne-Catherine Chapelle (Belgium) – Seeing Optic Neuritis Through Optical Coherence Tomography: a new biomarker \n\n\n\nSince the revised McDonald criteria now include the optic nerve as a fifth topographical location\, careful and precise neuro-ophthalmologic examination has become mandatory. Accurate diagnosis of optic neuritis relies on a comprehensive assessment\, including optical coherence tomography (OCT). This technique enables precise\, non-invasive quantification of the peripapillary retinal nerve fiber layer and the ganglion cell layer. In this keynote\, we will review the evidence linking OCT findings to the diagnosis of optic neuritis\, visual outcomes\, and disease activity\, as well as its role in monitoring disease evolution. These data highlight the growing relevance of OCT in both clinical practice and research. \n\n\n\nJette Latrup Frederiksen – Optic neuritis as a window to the brain: MRI and functional VEP \n\n\n\nThe 2024 revision of the McDonald criteria introduced a major change by including the optic nerve as the fifth anatomical location demonstrating dissemination in space (DIS)\, thereby enhancing the diagnostic sensitivity of MS. Not only MRI of the optic nerve\, but also VEP and OCT can confirm affection of the optic nerve. Thus structural as well as functional examinations of the visual pathways are important. This talk will mainly focus on imaging aspects (MRI of the optic nerve and brain) beyond OCT together with functional testing including VEP and multifocal VEP. \n\n\n\n\nVenue: The Irish College\, Leuven\, and Parking details \n        \n            \n              \n                        \n                            Address of the venue\n                        \n                    \n                        \n                            About this Irish College\n                        \n                    \n                        \n                            About the parking\n                        \n                    \n            \n            \n                \n\n\nLocation: Paridaensinstituut \n\n\n\nAddress : Janseniusstraat 1\, 3000 Leuven \n\n\n\nTelephone  : 016 31 04 30 \n\n\n\n\n\n \n\n\n\n\n\n\n\n\n\nThe Irish College Leuven was founded in 1607 and is one of the oldest Irish colleges on the European continent. It was established to educate Irish priests at a time when religious training was restricted in Ireland. Over the centuries\, the College became an important intellectual and cultural hub\, closely linked to the University of Leuven\, and played a key role in preserving Irish scholarship and heritage. Today\, it stands as a historical symbol of the long-standing academic and cultural ties between Ireland and Belgium. \n\n\n\n\n\nThe parking space is available near the venue. \n\n\n\nAccess & Parking \n\n\n\nBethlehem parking:  \n\n\n\nFree parking is available at Bethlehem Parking\, Leuven. The address is Redingenstraat 21\, 3000 Leuven\, approximately a 5-minute walk from the venue.Access code is: 15953#. \n\n\n\nGroup parking: Q-Park Heilig Hart \n\n\n\nAddress : Naamsestraat 102\, 3000 Leuven (≈ 10-minute walk to Irish College) \n\n\n\n \n\n\n\n            \n        \n        \n    \n\n\n\nFAQ \n\nHow can I register for the event?\nSimply click on REGISTRATION button you can see above this section and then select your admission ticket category \n\n\n\n\nCan I bring a guest?\nAbsolutely! You can register up to 5 persons per session\, if they are also healthcare professionals with a focus on neurology \n\n\n\n\nHow can I get updates or notifications about the meeting?\nStay connected with all updates and news by subscribing to the ParadigMS Foundation webpage: https://paradigms.foundation/ \n\n\n\n\nWill there be food and beverages provided?\nYes\, we provide a welcome coffee\, a coffee break and a networking lunch with a variety of drinks. \n\n\n\n\nWhat if I need to cancel my registration?\nIf you need to cancel your registration\, please send a message to learning@paradigms.foundation. \n\n\n\n\nIs there a dress code for the meeting?\nWe recommend wearing smart casual attire. \n\n\n\n\nWill the Annual MS meeting be live streamed?\nNo\, the live sessions of the meeting are not live streamed and available only for onsite participants. \n\n\n\n\nWho can I contact for additional information?\nIf you have any questions or need further information about either of the two learning experiences\, please feel free to reach out to us at learning@paradigms.foundation. \n\n\n\n\nWill there be a written report from the sessions?\nYes\, the ParadigMS Secretariat is planning to have a medical writer on site who will be tasked with producing a written report from both sessions. \n\n\n\n\nWill any of the sessions be recorded on video for later viewing?\nYes\, the keynotes will be video and audio recorded and will be made available on ParadigMS.foundation. You will need to create a Member account to have access to the recording (conditions to join as a member apply). \n\n\n\n\n\n\nSponsorships\nIn return for their sponsorship\, our sponsors receive visibility and can register a limited number of their staff to join the Meeting. Sponsors are not involved in the elaboration of the programme and presentations.  \n\n\n\n        \n            \n              \n                        \n                            Our gold sponsors\n                        \n                    \n                        \n                            Our bronze sponsors\n                        \n                    \n            \n            \n                \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n            \n        \n        \n    \n\n\nInterested to join as a sponsor? Please contact ParadigMS at secretariat@paradigms.foundation \n\n\n\n\n \n\n\n\nOrganized by
URL:https://paradigms.foundation/event/annual-ms-meeting-2026/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2025/12/AMS2026-PROD-banner-1080x655px-01.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260627T080000
DTEND;TZID=Europe/Paris:20260627T170000
DTSTAMP:20260511T075638Z
CREATED:20260511T075637Z
LAST-MODIFIED:20260511T075638Z
UID:14295-1782547200-1782579600@paradigms.foundation
SUMMARY:ParadigMS at EAN 2026
DESCRIPTION:We are excited to announce that ParadigMS will be present at the 12th Congress of the European Academy of Neurology (EAN) 2026\, taking place from June 27 to 30\, 2026\, at Palexpo in Geneva\, Switzerland. \n\n\n\nJoin us throughout the congress to discover the latest ParadigMS educational initiatives and resources dedicated to advancing care in Multiple Sclerosis (MS)\, Neuromyelitis Optica Spectrum Disorder (NMOSD)\, and MOG Antibody Disease (MOGAD). \n\n\n\nVisit our team in the Neurohood\, the dedicated networking and collaboration area for neurological organisations and partners. At our booth\, attendees will be able to explore: \n\n\n\n\nPeer-reviewed educational slide decks\n\n\n\nEACCME® accredited e-learning programmes\n\n\n\nScientific updates and practical clinical resources\n\n\n\nNew initiatives supporting multidisciplinary neurological care\n\n\n\n\nThe overarching theme of EAN 2026 is “Brains\, Bytes & Beyond: Tech in Neurology”\, highlighting how technological innovation and artificial intelligence are transforming neurological practice\, research\, and patient care. \n\n\n\nWe look forward to connecting with neurologists\, researchers\, healthcare professionals\, and partners from around the world in Geneva. \n\n\n\nFor more information about the congress\, visit: \n\n\n\n\nEAN Congress 2026
URL:https://paradigms.foundation/event/paradigms-at-ean-2026/
LOCATION:Palexpo Genova
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/05/Congress-of-the-European-Academy-of-Neurology-EAN-2026-1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260904T140000
DTEND;TZID=Europe/Paris:20260904T180000
DTSTAMP:20260901T123003Z
CREATED:20260603T145017Z
LAST-MODIFIED:20260901T123003Z
UID:14377-1788530400-1788544800@paradigms.foundation
SUMMARY:Scientific meeting: Multiple Sclerosis - Multiple Predictors in Disease Prognostication
DESCRIPTION:The scientific meeting chaired by ParadigMS expert Maura Pugliatti will be exploring current and emerging predictors of disease progression in Multiple Sclerosis.\n\n\n\nRegistration\n\n\n\nParticipation is free of charge\, but registration is required as places are limited. Please complete the registration form to confirm your attendance. \n\n\n\n\nRegister to attend the in-person scientific meeting\n\n\n\n\nMeeting details\n\n\n\nDate: Friday\, 4 September 2026Time: 13:00-18:10Location: Palazzo Roverella\, Ferrara\, ItalyRegistration: Free of chargeCME accreditation: No CME credits available \n\n\n\nUnderstanding disease progression remains one of the greatest challenges in Multiple Sclerosis (MS) care. This scientific meeting will bring together leading international experts to examine the diverse factors that contribute to disease prognostication\, from clinical and biological markers to emerging technologies and predictive models. \n\n\n\nParticipants will explore current evidence on pathophysiology\, biomarkers\, genetic studies\, registries\, comorbidities\, imaging\, and decision-support systems\, while discussing how these insights may support more personalized management strategies for people living with MS. \n\n\n\nDepliant_MS&NO_September4_DEFDownload\n\n\n\nDownload the programme \n\n\n\nScientific committee\n\n\n\n\nMaura Pugliatti\n\n\n\nCaterina Ferri\n\n\n\nNicola Merli\n\n\n\nMassimiliano Castellazzi\n\n\n\n\nProgramme overview\n\n\n\nSession I\n\n\n\nPrognostication in Multiple Sclerosis: Pathogenesis\, Pathophysiology and Clinical Presentation \n\n\n\n14:00Multiple sclerosis progression: pathophysiology and measurementsCelia Oreja-Guevara (Spain) \n\n\n\n14:20Clinical predictors of disease progressionBart Van Wijmeersch (Belgium) \n\n\n\n14:40Biomarkers in predicting multiple sclerosis worseningLaura Airas (Finland) \n\n\n\n15:00Prognostication from genetic studiesSandra D’Alfonso (Italy) \n\n\n\n15:20Investigating disease prognosis through data collection: the Italian MS RegistryPietro Iaffaldano (Italy) \n\n\n\n15:40Microchimerism in multiple sclerosisMichele Rubini (Italy) \n\n\n\n16:00Discussion \n\n\n\nSession II\n\n\n\nPrognostication in Multiple Sclerosis: Evidence About Less Conventional Predictors \n\n\n\n16:20Prognostication from cerebrospinal fluid analysisMassimiliano Castellazzi (Italy) \n\n\n\n16:40Comorbidities in multiple sclerosis progressionCaterina Ferri (Italy) \n\n\n\n17:00The role of ultrasound in prognosis through the study of the optic nerveNicola Merli (Italy) \n\n\n\nSession III\n\n\n\nPrognostication in Multiple Sclerosis: Moving Towards Algorithms and Decisional Support Systems \n\n\n\n17:20Decisional support systems\, modelling and algorithmsMassimiliano Copetti (Italy) \n\n\n\n17:40Prognostication in multiple sclerosis: the PROMISING StudyMaura Pugliatti (Italy) \n\n\n\n18:00Discussion \n\n\n\n18:10Closing remarksMaura Pugliatti (Italy) \n\n\n\nWhy attend?\n\n\n\nThis meeting offers a comprehensive overview of established and emerging predictors of disease progression in Multiple Sclerosis\, bringing together expertise from clinical practice\, epidemiology\, genetics\, biomarker research and data science. Attendees will gain practical insights into how prognostic tools may support more informed treatment decisions and personalised patient care. \n\n\n\nUnder the auspices of\n\n\n\n\nParadigMS\n\n\n\nUniversity of Ferrara\n\n\n\nFerrara University Hospital\n\n\n\nFerrara Health District\n\n\n\nItalian Society of Neurology (SIN)\n\n\n\nItalian Association of Neuroepidemiology (AINEP)\n\n\n\n\nSponsorships
URL:https://paradigms.foundation/event/scientific-meeting-multiple-sclerosis-multiple-predictors-in-disease-prognostication/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/06/Palazzo.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260905T083000
DTEND;TZID=Europe/Paris:20260905T134500
DTSTAMP:20260605T090440Z
CREATED:20260603T142911Z
LAST-MODIFIED:20260605T090440Z
UID:14355-1788597000-1788615900@paradigms.foundation
SUMMARY:ParadigMS Expert Meeting 2026
DESCRIPTION:Casa d’Este – Hotel Ferrara\, Italy\n\n\n\n\n\nPractical details\n\n\n\nDate: Saturday\, 5 September 2026Time: 08:30 -13:45Location: Casa d’Este – Hotel Ferrara\, ItalyAudience: ParadigMS expert members \n\n\n\nUpon invitation meeting only \n\n\n\nThe ParadigMS Expert Meeting 2026 will bring together international neurologists and Multiple Sclerosis (MS) experts to discuss current and emerging topics in demyelinating diseases. \n\n\n\nThe programme will focus on new therapies\, paediatric MS\, symptomatic treatment\, healthcare system impact on treatment choice\, disability progression\, BTK inhibitors\, and clinical management of Neuromyelitis Optica Spectrum Disorder (NMOSD)\, optic neuritis and MS. \n\n\n\nProgramme overview\n\n\n\n08:30–08:45Introduction to the meetingCelia Oreja-Guevara \n\n\n\n08:45–09:15New therapies in MGAndrew Chan\, Maura Pugliatti \n\n\n\n09:15–09:45Paediatric MSMagd Zakaria\, Carlo Pozzilli \n\n\n\n09:45–10:15Symptomatic therapies in Multiple SclerosisVeronica Popescu\, Bart Van Wijmeersch\, Carlo Pozzilli\, Melinda Magyari\, Patrick Vermersch \n\n\n\n10:15–10:45Coffee break \n\n\n\n10:45–11:20How healthcare system classification impacts treatment choice in Multiple SclerosisThomas Berger\, Tjalf Ziemssen\, Nikolaos Grigoriadis\, Magd Zakaria\, Melinda Magyari \n\n\n\n11:20–11:40Prognosis in Multiple SclerosisMaura Pugliatti \n\n\n\n11:40–12:00Uncovering Disability Progression in People with Multiple Sclerosis: A Practical GuideBart Van Wijmeersch\, ParadigMS Office team \n\n\n\n12:00–12:40Treatment landscape and approaches in the era of BTK inhibitors \n\n\n\n12:40–13:10Lunch \n\n\n\n13:10–13:30Diagnosis and clinical management of NMO/Optic Neuritis and MSKazuo Fujihara\, Celia Oreja-Guevara\, Melinda Magyari \n\n\n\n13:30–13:45ClosingCelia Oreja-Guevara \n\n\n\n\n	\n\n\n\n\nThe ParadigMS Expert Meeting will be sponsored by Roche\, Sandoz and Sanofi
URL:https://paradigms.foundation/event/paradigms-expert-meeting-2026-ferrara-italy/
LOCATION:Ferrara\, Italy
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/06/Castello-Estense.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20260929T163000
DTEND;TZID=Europe/Paris:20260929T173000
DTSTAMP:20260923T162319Z
CREATED:20260901T100648Z
LAST-MODIFIED:20260923T162319Z
UID:14730-1790699400-1790703000@paradigms.foundation
SUMMARY:Live Webinar on Paediatric Multiple Sclerosis
DESCRIPTION:Join this ParadigMS live webinar dedicated to Paediatric Multiple Sclerosis (MS) and explore expert perspectives on the challenges of recognising\, diagnosing and managing MS in children and adolescents. \n\n\n\nThe session will bring together leading experts to discuss current clinical considerations and provide practical insights relevant to neurologists and healthcare professionals involved in MS care. \n\n\n\nKey Highlights\n\n\n\n\nEpidemiology\, genetic and environmental factors in paediatric MS.\n\n\n\nDisease course\, smouldering disease and risk of persistent disability.\n\n\n\nNew diagnostic criteria and differential diagnosis\, including NMOSD and MOGAD.\n\n\n\nCSF\, imaging and blood biomarkers.\n\n\n\nNeuropsychological performance\, quality of life and psychological issues.\n\n\n\nPharmacological therapies and evolving treatment approaches.\n\n\n\nLong-term monitoring and support for younger patients and their families.\n\n\n\nQ&A on key clinical challenges.\n\n\n\n\nMore information & Learning Objectives to come soon \n\n\n\nFind out more about the speakers: \n\n\n\nSpeakers\n\n\n\n\nThais Armangué \n\n\n\nCarlo Pozzilli\n\n\n\n\nModerator\n\n\n\n\nValeria Pozzilli\n\n\n\n\nRegister\n\n\n\nThis session will be delivered live on Zoom. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nWhy participate?\n\n\n\n\nExplore the key clinical features of paediatric Multiple Sclerosis (MS)\n\n\n\nStrengthen diagnostic confidence in children and adolescents with suspected MS\n\n\n\nReview important differential diagnoses and challenges specific to paediatric-onset disease\n\n\n\nDiscuss current approaches to treatment selection and long-term disease management\n\n\n\nGain expert perspectives on monitoring disease activity and supporting care across the transition to adulthood\n\n\n\n\nWho should join?\n\n\n\n\nNeurologists and paediatric neurologists with an interest in Multiple Sclerosis\n\n\n\nMS specialists and neurologists in training\n\n\n\nNurses and other healthcare professionals involved in MS care\n\n\n\nHealthcare professionals involved in the diagnosis or management of paediatric demyelinating disorders\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nThe session will be held on Tuesday\, 29th September 2026 from 16:30 to 17:30 CEST. \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCarlo Pozzilli\n\n\n\n\nProfessor of Clinical Neuroscience at University of Rome “La Sapienza” \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nThaìs Armangué\n\n\n\n\nHead of the Department and attending in the Paediatric Neuroimmunology Unit at SJD Barcelona Children’s Hospital \n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nValeria Pozzilli\n\n\n\n\nNeurologist and researcher\, Queen Square MS Centre\, UCL Queen Square Institute of Neurology\, University College London\, United Kingdom \n\n\n\n\n\n\n\nRegistration\n\n\n\nRegistration is necessary and can be completed by clicking the button on top of this page or here: \n\n\n\n \n\n\n\n\nRegister now\n\n\n\n\nFunding\n\n\n\nThis webinar was organized with the financial support of Roche. \n\n\n\nRoche has not been involved in the elaboration of the presentations.
URL:https://paradigms.foundation/event/live-webinar-on-paediatric-multiple-sclerosis/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/09/PDMS-Live-webinar-banner-1080x655px_1.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20261029T170000
DTEND;TZID=Europe/Paris:20261029T180000
DTSTAMP:20261008T162216Z
CREATED:20260714T120304Z
LAST-MODIFIED:20261008T162216Z
UID:14577-1793293200-1793296800@paradigms.foundation
SUMMARY:Live Webinar on how healthcare system classification impacts treatment choice in multiple sclerosis
DESCRIPTION:Healthcare systems play a fundamental role in determining how people living with Multiple Sclerosis (MS) access diagnosis\, treatment and long-term specialist care. While scientific advances continue to expand therapeutic options\, differences in healthcare organisation\, reimbursement policies\, drug availability and clinical pathways create substantial variation in patient care across countries. \n\n\n\nIn this expert panel discussion\, Thomas Berger will moderate a conversation with leading European neurologists and Paradigms members to explore how healthcare systems influence the delivery of optimal MS care. Through country-specific perspectives and interactive discussion\, the panel examines practical challenges\, identifies successful approaches\, and considers how healthcare systems can evolve to improve access to high-quality care while making efficient use of available resources. \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLearning Objectives\n\n\n\nFollowing this webinar\, participants should be better able to: \n\n\n\n\nRecognize how differences in healthcare systems\, national guidelines and reimbursement policies can influence MS treatment choices and access to care.\n\n\n\nDiscuss the importance of balancing treatment costs with the broader clinical and societal burden of MS when considering healthcare resource allocation.\n\n\n\nExplore the role of neurologists\, multidisciplinary teams\, registries and real-world data in supporting evidence-based and integrated MS care.\n\n\n\nIdentify key considerations for sustainable access to high-quality MS treatments\, including treatment availability\, quality and continuity of supply.\n\n\n\nConsider opportunities to strengthen patient involvement in treatment decisions\, care delivery and data generation.\n\n\n\n\nWho should attend?\n\n\n\nThis webinar is intended for: \n\n\n\n\nClinically active neurologists\n\n\n\nMultiple Sclerosis specialists\n\n\n\nNeurology residents and trainees\n\n\n\nMS nurses and other healthcare professionals involved in multidisciplinary MS care\n\n\n\n\nThe webinar will be submitted for accreditation to the relevant Belgian authorities. \n\n\n\nRecording\n\n\n\nThe webinar recording is expected to be published on the ParadigMS educational platform following the live session. Access will be restricted to healthcare professionals. \n\n\n\nRegistration\n\n\n\nThis session will be delivered live on Zoom. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with  \n\n\n\nFind out more about the speakers: \n\n\n\nSpeakers\n\n\n\n\nThomas Berger (AT) (Moderator)\n\n\n\nMelinda Magyari (DK)\n\n\n\nNikolaos Grigoriadis (GR)\n\n\n\nJelena Drulovic (RS)\n\n\n\nMagd Zakaria (EG)\n\n\n\nTjalf Ziemssen (DE)\n\n\n\n\n\n\n\n\n\nThomas Berger\n\n\n\n\nProfessor of Neurology and Chair of the Dept. of Neurology at the Medical University of Vienna  \n\n\n\n\n\n\n\n\n\n\n\n\nMagd Zakaria\n\n\n\n\nHead of the Multiple Sclerosis Unit at the Ain Shams Specialized University Hospital  \n\n\n\n\n\n\n\n\n\n\n\n\nMelinda Magyari\n\n\n\n\nDirector of the Danish Multiple Sclerosis Registry \n\n\n\n\n\n\n\n\nTjalf Ziemssen\n\n\n\n\nProfessor of Clinical Neuroscience at University Clinic Carl-Gustav Carus in Dresden \n\n\n\n\n\n\n\n\n\n\n\n\nNikolaos Grigoriadis\n\n\n\n\nProfessor of Neurology at the Aristotle University of Thessaloniki \n\n\n\n\n\n\n\n\n\n\n\n\nJelena Drulovic\n\n\n\n\nProfessor of Neurology at the Faculty of Medicine\, University of Belgrade \n\n\n\n\n\n\n\nFunding \n\n\n\nThis webinar was organized with the financial support of Sandoz. \n\n\n\nSandoz has not been involved in the elaboration of the presentations.
URL:https://paradigms.foundation/event/how-healthcare-system-classification-impacts-treatment-choice-in-multiple-sclerosis/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/07/PMS-PROD-webinar-261029-banner-1080x655px.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20261123T170000
DTEND;TZID=Europe/Paris:20261123T181500
DTSTAMP:20261020T144017Z
CREATED:20260804T090238Z
LAST-MODIFIED:20261020T144017Z
UID:14645-1795453200-1795457700@paradigms.foundation
SUMMARY:Live Webinar: A Biosimilar in Multiple Sclerosis Care in Belgium: Evidence\, Confidence and Implementation
DESCRIPTION:Live webinar | Online \n\n\n\nJoin a 75-minute expert-led webinar examining the clinical\, regulatory and practical considerations involved in introducing a biosimilar into Multiple Sclerosis (MS) care in Belgium. \n\n\n\nThe programme will combine Belgian healthcare perspectives with experience from France and practical insights into MS-centre workflows. Participants will also have the opportunity to discuss implementation questions during an extended panel discussion and Q&A. \n\n\n\n\nRegister for the live webinar\n\n\n\n\nAbout the webinar\n\n\n\nWith the expected introduction of a biosimilar treatment option in Belgian MS care\, neurologists need clear and independent education on how biosimilars are assessed\, approved and implemented. \n\n\n\nThis webinar will address the regulatory principles and clinical evidence supporting biosimilars\, including how they differ from generics. It will also consider how international experience may inform decision-making in Belgium. \n\n\n\nThe faculty will discuss practical implementation in daily MS care\, including communication with people living with MS\, shared decision-making\, infusion-centre pathways\, multidisciplinary coordination and monitoring procedures. \n\n\n\nLearning objectives\n\n\n\nBy the end of the webinar\, participants will be able to: \n\n\n\n\nExplain the regulatory framework for biosimilars and how biosimilars differ from generics.\n\n\n\nRelate experience from the introduction of a biosimilar in France to the Belgian context.\n\n\n\nDiscuss practical approaches to patient communication\, infusion pathways and monitoring when implementing biosimilars in MS care.\n\n\n\nSupport informed discussion about biosimilars with multidisciplinary care teams and people living with Multiple Sclerosis.\n\n\n\nConsider the practical implications of biosimilar implementation for MS-centre workflows.\n\n\n\n\nWho should attend?\n\n\n\nThis webinar is intended for: \n\n\n\n\nClinically active neurologists based in Belgium\n\n\n\nMultiple Sclerosis specialists\n\n\n\nNeurology residents and trainees\n\n\n\nMS nurses and other healthcare professionals involved in multidisciplinary MS care\n\n\n\n\nThe webinar will be submitted for accreditation to the relevant Belgian authorities. \n\n\n\nRecording\n\n\n\nThe webinar recording is expected to be published on the ParadigMS educational platform following the live session. Access will be restricted to healthcare professionals. \n\n\n\nRegistration\n\n\n\nThis session will be delivered live on Zoom. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\n\nRegister for the live webinar\n\n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nFind out more about the speakers:\n\n\n\nProf. Bart Van Wijmeersch\n\n\n\nChair and moderator \n\n\n\nNeurologist and Medical Director at the Rehabilitation & MS Center in Pelt\, Belgium\, and Associate Professor at Hasselt University. \n\n\n\nDr Serena Borrelli\n\n\n\nSpeaker  \n\n\n\nNeurologist and Medical Doctor at Univertsité Libre de Bruxelles\, Belgium \n\n\n\nProf. Jérôme de Sèze\n\n\n\nSpeaker  \n\n\n\nNeurologist at Strasbourg University Hospitals and Head of the MS Expert Centre / CRC SEP in France. \n\n\n\nPiet Eelen\, RN\, MSc\n\n\n\nSpeaker  \n\n\n\nClinical Nurse Specialist in Multiple Sclerosis at the National MS Center in Melsbroek\, Belgium. \n\n\n\nFunding\n\n\n\nThis webinar was organized with the financial support of Sandoz. \n\n\n\nSandoz has not been involved in the elaboration of the presentations.
URL:https://paradigms.foundation/event/live-webinar-a-biosimilar-in-multiple-sclerosis-care-in-belgium-evidence-confidence-and-implementation/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/08/paradigms-foundation-webinar-biosimilars-in-belgium-002.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20261127T123000
DTEND;TZID=Europe/Paris:20261127T190000
DTSTAMP:20261021T134302Z
CREATED:20260714T094238Z
LAST-MODIFIED:20261021T134302Z
UID:14567-1795782600-1795806000@paradigms.foundation
SUMMARY:Paradigms Regional MS Symposium
DESCRIPTION:Co-organized by the Hungarian Neuroimmunology Society and by ParadigMS Foundation\, the Symposium is specifically designed to address the clinical and educational needs of the region. \n\n\n\nThe meeting will take place in Szeged\, Hungary.\n\n\n\n\n\n\n\n\nRegister to join the IN-PERSON meeting\n\n\n\n\nMeeting details\n\n\n\nDate: Friday\, 27 November 2026Time: 12:30-19:05Location: ART Hotel\, Szeged\, 6720 Somogyi u. 16m\, Hungary \n\n\n\nOrganised by: Paradig:S and the Hungarian Neuroimmunology Society \n\n\n\nAdvances in the management of neuroimmunological diseases continue to raise new clinical questions. This regional symposium will provide an interactive forum where experts discuss real-world therapeutic challenges in Multiple Sclerosis (MS)\, Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Through case presentations\, panel debates and evidence-based lectures\, participants will explore practical approaches to diagnosis\, treatment optimisation and regional clinical practice. \n\n\n\nVenue\n\n\n\nART HotelSomogyi u. 16\, 6720 Szeged\, Hungary \n\n\n\n\n\n\n\nScientific committee\n\n\n\n\nCecilia Rajda\n\n\n\nMelinda Magyari\n\n\n\nGregor Brecl Jakob\n\n\n\nMario Habek\n\n\n\nRodica Balasa\n\n\n\nJelena Drulovic \n\n\n\n\nProgramme overview\n\n\n\nParadigMS Regional MS Symposium_Szeged 2026 – Programme 0210Download\n\n\n\n\n\n\n\nWhy attend?\n\n\n\nThis regional symposium offers an opportunity to engage with leading experts on current therapeutic challenges in Multiple Sclerosis (MS)\, Neuromyelitis Optica Spectrum Disorder (NMOSD) and Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD). Through debate-style sessions\, case-based learning and expert presentations\, participants will gain practical insights into treatment optimisation\, evolving diagnostic criteria\, long-term risk mitigation and region-specific approaches to patient management. \n\n\n\nOrganised by\n\n\n\n\nHungarian Neuroimmunology Society\n\n\n\nParadigms Foundation\n\n\n\n\n        \n            \n              \n                        \n                            Hungarian Neuroimmunology Society\n                        \n                    \n                        \n                            Paradigms Foundation\n                        \n                    \n            \n            \n                \n\n\n \n\n\n\n\n\n\n\n\n\n\n\n\n\n \n\n\n\n            \n        \n        \n    \n\n\nOur Partners \n\n\n\n        \n            \n              \n                        \n                            Amgen\n                        \n                    \n                        \n                             AstraZeneca\n                        \n                    \n                        \n                            Merck\n                        \n                    \n                        \n                            Neuraxpharm\n                        \n                    \n                        \n                            Novartis\n                        \n                    \n                        \n                             QPharma \n                        \n                    \n                        \n                             \n                        \n                    \n                        \n                            Richter Gedeon\n                        \n                    \n                        \n                            Roche \n                        \n                    \n                        \n                            Sandoz\n                        \n                    \n                        \n                            Teva
URL:https://paradigms.foundation/event/paradigms-regional-ms-symposium-2/
ATTACH;FMTTYPE=image/jpeg:https://paradigms.foundation/wp-content/uploads/2026/07/PMS-PROD-Regional-Symposium-2026-banner-1080x655px-02.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20261203T134500
DTEND;TZID=Europe/Paris:20261203T144500
DTSTAMP:20260922T100812Z
CREATED:20260922T100423Z
LAST-MODIFIED:20260922T100812Z
UID:14932-1796305500-1796309100@paradigms.foundation
SUMMARY:Paradigms pre-MENACTRIMS Symposium 2026
DESCRIPTION:Intercontinental Festival City\, Dubai\, United Arab Emirates \n\n\n\nAdvancing Multiple Sclerosis Care Across the Middle East and North Africa\n\n\n\nMENACTRIMS\, the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis\, is a regional scientific organisation dedicated to advancing knowledge\, research\, education and clinical care in multiple sclerosis (MS) and related neuroimmunological disorders across the Middle East and North Africa. \n\n\n\nMENACTRIMS brings together neurologists\, researchers\, healthcare professionals and experts from across the region and internationally\, creating a platform for scientific exchange\, collaboration and education. \n\n\n\nThrough its scientific and educational activities\, MENACTRIMS aims to support healthcare professionals in navigating a rapidly evolving MS landscape and translating advances in research\, diagnosis\, monitoring and treatment into meaningful improvements in clinical practice. \n\n\n\nParadigMS Pre-MENACTRIMS Symposium\n\n\n\nFrom Biomarkers to Better Decisions in Multiple Sclerosis\n\n\n\nHeld in conjunction with MENACTRIMS\, the ParadigMS Pre-MENACTRIMS Symposium is a focused scientific and educational meeting bringing together experts in multiple sclerosis to explore how emerging tools and biomarkers can support more personalised approaches to MS management. \n\n\n\nAs the MS treatment landscape becomes increasingly complex\, clinicians have access to a growing range of information beyond conventional clinical assessment. Advanced imaging\, fluid biomarkers and digital technologies offer new possibilities for detecting disease activity\, evaluating treatment response and identifying patients who may be at greater risk of progression. \n\n\n\nThe symposium will examine how these developments can move from scientific promise towards meaningful application in everyday clinical practice. \n\n\n\nKey Takeaways\n\n\n\n\nHow technological\, imaging and fluid biomarkers may contribute to more personalised MS treatment decisions.\n\n\n\nWhich biomarker signals may help identify subclinical disease activity\, treatment response and progression risk.\n\n\n\nThe role of imaging biomarkers in monitoring inflammatory activity\, neurodegeneration and smouldering disease.\n\n\n\nHow serum neurofilament light chain and other fluid biomarkers may be interpreted in clinical practice.\n\n\n\nHow digital and wearable technologies may complement clinic-based assessment by capturing real-world function over time.\n\n\n\nThe key limitations\, confounding factors and standardisation issues affecting biomarker interpretation.\n\n\n\nHow biomarker information can be integrated with clinical judgement\, MRI findings\, patient characteristics and treatment goals.\n\n\n\nWhich biomarkers are closest to routine clinical implementation and which remain primarily investigational.\n\n\n\nHow biomarker strategies may be adapted to different healthcare systems and levels of resource availability.\n\n\n\n\nWith thanks to our sponsor\, who supports this event without any involvement in the elaboration of the presentations.
URL:https://paradigms.foundation/event/paradigms-pre-menactrims-symposium-2026/
ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2026/09/Banner-MENACTRIMS-2026.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Paris:20261221T170000
DTEND;TZID=Europe/Paris:20261221T180000
DTSTAMP:20260922T101743Z
CREATED:20260902T100219Z
LAST-MODIFIED:20260922T101743Z
UID:14751-1797872400-1797876000@paradigms.foundation
SUMMARY:Live Webinar on the new therapies in Myasthenia Gravis
DESCRIPTION:Live webinar | Monday 21 December 2026 | 17:00–18:00 CET \n\n\n\nJoin this live ParadigMS webinar for an expert-led discussion on new and emerging therapies in myasthenia gravis\, with a focus on their relevance for clinical practice. \n\n\n\nDuring this one-hour session\, Andrew Chan\, Maura Pugliatti and Celia Oreja-Guevara will review current developments and discuss how advances in treatment may influence therapeutic decision-making. \n\n\n\nThe session will bring together leading experts to discuss current clinical considerations and provide practical insights relevant to neurologists and healthcare professionals involved in MS care. \n\n\n\nRegister to join the live webinar and hear perspectives from leading neurology experts. \n\n\n\nKey Highlights\n\n\n\nThe session will provide an expert overview of the changing treatment landscape in myasthenia gravis and its implications for clinical practice. Participants will have the opportunity to: \n\n\n\n\nExplore recent developments in therapies for myasthenia gravis.\n\n\n\nReview the evolving therapeutic landscape.\n\n\n\nConsider the clinical relevance of new treatment options.\n\n\n\nHear expert perspectives on treatment decision-making.\n\n\n\nJoin the discussion during the live session.\n\n\n\n\nMore information & Learning Objectives to come soon\n\n\n\nRegister\n\n\n\nThis session will be delivered live on Zoom. Don’t miss this opportunity and register now to make sure you book your place and take part in knowledge exchange and discussions!  \n\n\n\nLanguage\n\n\n\nThe session will be held in English with translated auto-captions into many languages (offered by Zoom platform). \n\n\n\nWho should attend?\n\n\n\n\nNeurologists and paediatric neurologists with an interest in Multiple Sclerosis\n\n\n\nMS specialists and neurologists in training\n\n\n\nNurses and other healthcare professionals involved in MS care\n\n\n\nHealthcare professionals involved in the diagnosis or management of paediatric demyelinating disorders\n\n\n\n\nQuestions and comments\n\n\n\nShould you have specific questions\, you would like to see discussed\, please share them with learning@paradigms.foundation now\, so the speakers could relate to them in their presentations.  \n\n\n\nYou will also have the opportunity to ask questions in person and participate in discussion during the webinar and the Q&A session. \n\n\n\nTechnology used\n\n\n\nThe webinar takes place via Zoom\, you will receive connection details upon registration. \n\n\n\nDate and time\n\n\n\nDate: Monday 21 December 2026Time: 17:00-18:00 CETFormat: Live online webinarDuration: 60 minutes \n\n\n\nSpeakers\n\n\n\nFind out more about the speakers: \n\n\n\n\n\n\n\nCelia Oreja-Guevara \n\n\n\nVice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos\, Madrid \n\n\n\n\n\n\n\nAndrew Chan \n\n\n\nHead of the Medical Division Neuro at the Bern University Hospital \n\n\n\n\n\n\n\nMaura Pugliatti \n\n\n\nProfessor of Neurology at the University of Ferrara \n\n\n\nFunding\n\n\n\nThis webinar is funded with ParadigMS own funds. No other sponsors have been invited to support this webinar.
URL:https://paradigms.foundation/event/new-therapies-in-myasthenia-gravis/
ATTACH;FMTTYPE=image/png:https://paradigms.foundation/wp-content/uploads/2026/09/New-therapies-in-MG.png
END:VEVENT
END:VCALENDAR